The HNF4α-caGR fusion transcription factor is an innovative therapeutic protein designed to restore liver function and reduce inflammation in liver diseases and liver cancer by simultaneously activating key regulatory pathways.
Liver diseases and liver cancer often involve impaired function of hepatocyte nuclear factor 4α (HNF4α) and glucocorticoid receptor (GR) pathways, leading to disrupted hepatocyte differentiation, metabolism, and anti-inflammatory responses. Traditional treatments struggle to effectively target these transcriptional deficiencies due to resistance mechanisms and widespread systemic side effects, creating a critical need for a targeted therapeutic approach that can overcome these challenges.
The HNF4α-caGR fusion transcription factor combines the functional domains of hepatocyte nuclear factor 4α (HNF4α) and a constitutively active glucocorticoid receptor (caGR) into a single engineered protein. This fusion enables cooperative DNA binding and transcriptional activation at specific gene sites that are essential for liver cell differentiation, metabolic regulation, and anti-inflammatory processes. By enforcing this cooperative engagement, the fusion factor effectively bypasses the usual transcriptional resistance seen in diseased liver cells. Unlike conventional glucocorticoid therapies that trigger widespread gene activation and significant systemic toxicity, this fusion selectively targets genes critical to liver health, minimizing off-target effects. The modular design of the fusion factor allows for further modifications to optimize its functional properties, such as enhancing DNA binding specificity or improving delivery to liver cells. This targeted approach not only restores key pathways simultaneously but also reduces harmful side effects, offering a novel geometry-driven strategy for transcriptional therapy.
Photo for reference only, not a depiction of the invention.
• Dual Pathway Restoration: Simultaneously reactivates both HNF4α and GR pathways critical to liver cell function.
• Selective Activation: Precisely targets specific genes, reducing unwanted effects on non-target tissues.
• Overcoming Resistance: Effective for treating conditions that are resistant to traditional glucocorticoid treatments.
• Reduced Toxicity: Liver-focused delivery limits systemic exposure and associated adverse effects.
• Modular Design: Allows customization to improve efficacy, specificity, and delivery options.
• Broad Applicability: Useful across a range of liver-related diseases and other inflammatory or systemic conditions.
• Treatment of inflammatory liver diseases, including hepatitis and fibrosis.
• Therapeutic approach for liver cancers by restoring normal transcriptional regulation.
• Potential use in managing systemic inflammatory conditions such as sepsis.
• Gene regulation therapies aimed at correcting transcriptional dysregulation in various diseases.
Patent pending
Inquire for stage of development
This technology is available for licensing.